



ASX/Media Release

14 September 2015

ASX code: PIQ

Non-renounceable Pro-rata Options Entitlement Issue

Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the **Company, PIQ**) is pleased to announce a non-renounceable pro-rata options entitlement issue to shareholders (**Entitlement Issue**).

The Entitlement Issue will offer eligible PIQ shareholders the opportunity to apply for 1 new option (**New Option**), to subscribe for ordinary shares, for every 4 existing ordinary shares held at an offer price of A\$0.01 per New Option. Each New Option may be exercised at any time from the date of issue until 31 March 2018 at an exercise price of A\$0.20 each.

It is anticipated that up to 12.6 million New Options may be issued pursuant to the Entitlement Issue, which would raise approximately A\$126,000 before costs.

The Entitlement Issue is fully underwritten by Sydney-based corporate advisory firm, K S Capital Pty Ltd.

The Entitlement Issue was outlined in PIQ's IPO prospectus, dated 10 November, 2014, and offers eligible shareholders the opportunity to share in the growth of the Company. Funds raised under the Entitlement Issue will be used to strengthen the Company's balance sheet and as general working capital. Further information on PIQ is included at the foot of this announcement.

Eligibility

Shareholders holding PIQ shares as at 5:00pm AWST on Friday 18 September 2015 (**Record Date**) will be entitled to participate in the Entitlement Issue. The Entitlement Issue is only open to PIQ shareholders with registered addresses in Australia and New Zealand as at the Record Date.

Fractional entitlements to New Options under the Entitlement Issue will be rounded up to the nearest whole number.

Prospectus

The Entitlement Issue is offered pursuant to a prospectus dated 11 September 2015. The Prospectus and Entitlement and Acceptance Forms will be sent to eligible PIQ shareholders on Monday, 21 September 2015.

The Company will seek quotation of the New Options issued pursuant to the Prospectus on the ASX.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008 Broadway, Nedlands, Perth WA 6009, Australia

T: +61 8 9389 1992 | F: +61 8 6151 1038 | E: enquiries@proteomicsinternational.com | W: proteomicsinternational.com

Indicative timeline

Applications under the Entitlement Issue must be received by PIQ's share registry by no later than 5:00pm AWST on Friday, 9 October 2015.

It is anticipated that issue of the New Options and despatch of holding statements will take place on Friday, 16 October 2015.

All future dates specified in this announcement are indicative and may be subject to change.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Media and Investor Inquiries
James Moses
Mandate Corporate
T: +61 420 991 574
E: james@mandatecorporate.com.au

Greg Wood
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

About Proteomics International Laboratories

PILL is an ASX listed (ASX: PIQ) life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics is an integral part of the biotechnology and life sciences industries and plays a key role in understanding disease and biological systems. It represents a massive global market estimated to be worth \$20.8 billion by 2018.

PILL is recognised as a global leader in its field. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company's business model uses its proprietary technology platform which operates across three synergistic proteomics-based business units in massive growth markets:

- 1. Analytical services:** Specialist contract research, analytical testing and consultancy - fee for service model.
- 2. Diagnostics:** Biomarkers of diseases and personalised medicine - focus on diabetic kidney disease and Alzheimer's disease. The biomarkers market is estimated to double in size to \$45.6 billion by 2020.
- 3. Drug discovery:** Therapeutic drug discovery with a focus on painkillers and antibiotics. The peptide therapeutics market is currently estimated to be worth \$17 billion.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008 Broadway, Nedlands, Perth WA 6009, Australia

T: +61 8 9389 1992 | F: +61 8 6151 1038 | E: enquiries@proteomicsinternational.com | W: proteomicsinternational.com